Structure-activity relationship

Structure-activity relationship (SAR) is the systematic mapping between a molecule's structural features and the biological activity those features produce. Researchers build it by synthesising a series of related compounds — each differing in one or a few chemical details — and measuring how each change shifts potency, selectivity, duration, or toxicity at the relevant biological target.

The result is not a law but a predictive model. SAR identifies which parts of a molecule are essential for activity, which can be modified, and — within limits — what a structurally similar but untested compound is likely to do. The inference can be reliable for closely related analogues and unreliable for more distant ones.

How it works · its role

Every molecule's activity at a receptor depends on its shape, size, polarity, and charge distribution — the features that determine how well it fits a binding site and how it perturbs the receptor once bound. When a chemist replaces a hydrogen with a methyl group, adds a halogen to an aromatic ring, or shifts a double bond, they alter that fit.

By tracking how potency rises or falls with each modification, researchers identify the pharmacophore: the minimal set of structural features required for activity. Modifications outside the pharmacophore can tune ancillary properties — solubility, metabolism, half-life — without destroying the core effect. Modifications inside it tend to reduce or abolish activity, or occasionally convert an agonist into an antagonist.

Relevance to substances & effects

SAR is the underlying logic for understanding chemical families of psychoactives. The tryptamine scaffold — shared by psilocin, DMT, and 5-MeO-DMT — accounts for the affinity these compounds share at 5-HT₂A and related receptors, and for their broadly convergent phenomenology despite differing potencies and durations.

The same logic runs across other families. The phenethylamine scaffold gives mescaline, MDMA, and the 2C series a common structural ancestry; differences in substitution patterns drive the divergence between stimulant, entactogenic, and psychedelic effects. Benzodiazepines share a diazepine ring fused to a benzene; modifications to that core shift the balance between anxiolytic, sedative, and anticonvulsant activity.

SAR also explains how novel psychoactive substances arise. Small structural modifications to a controlled compound can produce an analogue not yet scheduled, while retaining much of the parent compound's effect profile.

Because the prediction rests on structural analogy rather than direct measurement, the actual pharmacology of untested analogues can diverge in ways SAR alone does not anticipate — particularly for metabolic pathways, off-target activity, and toxicity. This is why class-level statements on these pages carry the caveat that they describe an expected profile, not a confirmed one.